262 related articles for article (PubMed ID: 28752222)
1. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
Džombeta T; Krušlin B
Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
4. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
5. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
6. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
8. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
9. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
[TBL] [Abstract][Full Text] [Related]
10. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.
Pan CC; Chang YH; Chen KK; Yu HJ; Sun CH; Ho DM
Am J Clin Pathol; 2010 May; 133(5):788-95. PubMed ID: 20395527
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
[TBL] [Abstract][Full Text] [Related]
13. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.
Florianova L; Xu B; Traboulsi S; Elmansi H; Tanguay S; Aprikian A; Kassouf W; Brimo F
World J Surg Oncol; 2015 Nov; 13():317. PubMed ID: 26577765
[TBL] [Abstract][Full Text] [Related]
15. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
[TBL] [Abstract][Full Text] [Related]
17. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
18. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases.
Toll AD; Epstein JI
Am J Surg Pathol; 2012 Jul; 36(7):1081-6. PubMed ID: 22510761
[TBL] [Abstract][Full Text] [Related]
19. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.
Lee TK; Chaux A; Karram S; Miyamoto H; Miller JS; Fajardo DA; Epstein JI; Netto GJ
Hum Pathol; 2011 Nov; 42(11):1799-803. PubMed ID: 21777949
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
